B-MoGen Biotechnologies and CytoSen Therapeutics Sign an Agreement for the Development of Gene-Modified Therapies

 B-MoGen Biotechnologies and CytoSen Therapeutics Sign an Agreement for the Development of Gene-Modified Therapies

B-MoGen Biotechnologies and CytoSen Therapeutics Sign an Agreement for the Development of Gene-Modified Therapies

Shots:

  • The companies collaborated to develop gene-modified NK Cell therapies using CARs (Chimeric antigen receptor) and TCRs (T cell receptors) in the fields of oncology
  • The focus of the agreement is to advance NK cell therapies with a reduction in its cost, combining B-MoGen’s genetic competence & its non-viral gene delivery platform with CytoSen’s nanoparticle technology
  • B-MoGen’s TcBuster is a non-viral transposon-based gene therapy technology used for developing T-Cell immunotherapies for multiple therapy areas

Click here to read full press release/ article | Ref: B-MoGen | Image: Lifenginetech

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post